Insights on Clinical Trials

  1. Precision Medicine: Targeted Cancer Therapies 10/2/2025

    Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

  2. Specialized Site Network For Early-Phase Oncology Success 10/2/2025

    Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

  3. Benefits Of Working With Catalyst Oncology Versus A Large Generalist CRO 10/2/2025

    Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

  4. Key Takeaways From ADCs In Oncology Trials Webinar 10/2/2025

    By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

  5. BlueRock Advances Cell Therapy For Parkinson's Disease 9/30/2025

    BlueRock Therapeutics has advanced its allogeneic stem cell-derived therapy bemdaneprocel into the pivotal Phase III trial for Parkinson’s disease, aiming to restore regulated dopamine signaling, improve quality of life, and potentially transform the treatment paradigm.

  6. What Do Cancer Patients Really Want From mHealth Technology? 9/30/2025

    What do cancer patients really want from apps and wearables? This piece reveals how patient perspectives can guide mHealth design to reduce burden, build trust, and make digital oncology tools truly meaningful.

  7. Rethinking Recruitment: Patient-Centric Strategies For The Future Of Clinical Trials 9/30/2025

    For sponsors and CROs, the message is clear: recruitment must be redesigned for accessibility, inclusivity, and patient trust.

  8. Navigating Adverse Immunostimulation: A Practical Guide For Clinical Researchers 9/30/2025

    Explore a systematic approach to evaluate adverse immunostimulation (AIS) in drug development through standardized biomarker sampling and tailored management strategies.

  9. Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit 9/26/2025

    OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.

  10. Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) 9/25/2025

    The Bayesian Logistic Regression Model (BLRM) is redefining Phase I clinical trial design by bringing flexibility, precision, and patient-centered safety into early drug development.